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Dyslipidemia is one of the possible risk factors for
advanced atherosclerosis in patients with chronic renal failure.
Abnormal phospholipid metabolism may play an important role
in the progression of atherosclerosis in patients with renal failure.
The aim of this study was to determine specific characteristics
of plasma and erythrocyte phospholipid content and fatty acid
composition in 37 patients with chronic renal failure on hemo-
dialysis (HD). The results were compared with the characteris-
tics of healthy subjects. Briefly, plasma triglyceride (p < 0.001),
total cholesterol (p < 0.05), and total phospholipids (p < 0.01)
levels were significantly higher and HDL-cholesterol level sig-
nificantly lower (p < 0.01) in HD patients. Plasma phosphati-
dylcholine and phosphatidylethanolamine concentration were
significantly higher (p < 0.001) in HD patients. The plasma
phospholipid fatty acids composition indicated significantly
(p < 0.01) higher level of oleic (18:1 n-9) and lower levels of
eicopentaenoic (20:5 n-3 EPA) and docosahexaenoic (22:6 n-3
DHA) acids (p < 0.05). However, in HD patients, the relative
concentration of plasma phospholipid n-6 polyunsaturated
fatty acid (PUFA) was significantly lower (p < 0.05). The
fatty acid composition of erythrocyte phospholipid in HD
patients was modified with EPA and DHA levels significantly
lowered (p < 0.05). Our results demonstrate an abnormal
phospholipid metabolism and deficiency of n-3 PUFA in
plasma and erythrocyte phospholipids in hemodialyzed patients.
Keywords lipids, phospholipids, fatty acids, plasma,
erythrocyte, hemodialysis
INTRODUCTION
Several abnormalities of lipid metabolism occur in
patients with chronic renal failure.[1,2] In these patients,
dyslipidemia is a characteristic feature and has been impli-
cated in the pathogenesis of cardiovascular complica-
tions.[3,4] Compared with the general population, those
with end-stage renal disease have a substantially elevated
risk of death from cardiovascular disease. Statistics show
that 50–60% of all deaths among dialysis patients are sec-
ondary to cardiovascular complication.[5] The most com-
mon plasma lipid abnormalities in patients with chronic
renal failure on hemodialysis are high triglycerides, small
LDL particles, and low HDL-cholesterol.[6,7] The lipopro-
tein abnormalities and hemodialysis appear to be the result
of impaired lipoprotein catabolism. A number of investi-
gations have shown that the activities of lipoprotein lipase,
hepatic triglyceride lipase, and lecithin cholesterol acyl-
transferase (LCAT) are reduced in chronic renal failure.[2]
LCAT deficiency is common in uremia and is associated
with changes not just in plasma lipids but also in mem-
brane lipids, which may be relevant to the progression of
chronic renal disease.[8]
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Phospholipids play an essential role in membrane
structure and function. The length and degree of unsat-
urated membrane phospholipids fatty acids are main
determinants of fluidity, transport systems, activity of
membrane-bound enzymes, and susceptibility to lipid
peroxidation.[9–11] The fatty acid profile of serum lipid,
especially the phospholipids, reflects the fatty acid com-
position of cell membranes.[12] There are limited and
inconclusive data, which deal with changes in fatty acid
metabolism and in fatty acid composition of plasma phos-
pholipids in chronic renal failure.[13–15] Erythrocytes can
alter phospholipids fatty acids composition only by the
exchange of intact molecules with plasma lipids but can-
not alter fatty acid chain length or the degree of unsatu-
ration. It has been established that erythrocytes reflect
the general fatty acid metabolism in other organs and
tissues.[16,17] The aim of this study was to determine spe-
cific characteristics of plasma and erythrocyte phospholip-
ids content and fatty acid composition in patients with
chronic renal failure on hemodialysis.
METHODS
Patients
The study was carried out in 37 chronic renal failure
patients from the Department of Nephrology, University
Hospital Zemun, Belgrade. All patients (21 male, 16 female,
mean age 52 ± 10 years, range 42–64) had been on mainte-
nance hemodialysis three times a week. The patients were
clinically stable, with adequate nutrition/inflammatory sta-
tus and with no recorded cardiovascular events (coronary
heart disease and cerebrovascular disease). The mean body
mass index (BMI) calculated from dry body weight was
23.65 ± 3.52 kg/m2 (range 19.8–27.3). Serum albumin con-
centration was 41.1 ± 2.9g/L and serum C-reactive protein
level was 3.08 ± 1.48 mg/mL. Patients’ characteristics and
their primary renal disease are shown on Table 1.
Patients with a history of nephrotic syndrome, diabe-
tes mellitus, alcohol consummation, systemic illness, or
any other disease that might influence lipid metabolism
were excluded. None of the patients received lipid lower-
ing drugs, L-carnitine or β-blockers in the 3 months prior
to entering the study. However, 25 patients with hyperten-
sion received treatment angiotensin-converting enzyme
inhibitors. Patients received no other medications except
multivitamins, calcitriol phosphate binders, and/or iron.
Patients maintained their habitual diets (35 kcal/kgbw,
protein intake 1–1.2 g/kgbw, fats <35% caloric intake)
with sodium and potassium restriction during the previous
3 months. They had low habitual consumption of foods
containing soy, fish intake once a week, and no dietary
supplementation of oil rich in long-chain fatty acid (fish,
sesame, or linseed oil) as determined by diet assessment
made at the time of recruitment. Blood samples were
drowning from their fistula before dialysis and after a 12-
to 14-h overnight fast. Blood samples were collected from
29 healthy volunteers (control group) from medical staff
and blood donors (17 males, 12 females, mean age 55 ± 9
years, range 44–62) after a 12-h overnight fast. All
patients signed an informed consent document. Study pro-
tocol was approved by the Medical Ethics Committee
(Institute for Medical Research, Belgrade) and conducted
in line with the principles of good scientific practice.
Biochemical Determination
Serum samples were prepared by 4°C centrifugation
of venous blood collected after 12- to 14-h fast. Total
serum cholesterol and triglyceride level were measured
spectrophotometrically by using a colorimetric enzymatic
reaction (EliTech Diagnostic, Sées, France). Serum albumin
concentration was determined by using bromcresolgreen
reagent (EliTech Diagnostic). HDL-cholesterol was deter-
mined by measuring the cholesterol in supernatant liquid
after serum precipitation with phosphotungstic acid, mag-
nesium chloride, and LDL-cholesterol was estimated by
using Friedewald formula.[18,19] Total phospholipids were
determined by the method of Zilversmit and Davis.[20]
C-reactive protein (CPR) level was measured with a
ELISA test (EliTech Diagnostic), with rabbit antibodies to
human CRP. Values <6 mg/L were considered normal.
Plasma lipids were extracted with chloroform-
methanol mixture (2:1 v/v) by Sperry and Brand method.[21]
Plasma phospholipids were separated by thin-layer
chromatography (TLC) into four fractions [i.e., lyso-
phosphatidylcholine (LPC), phosphatidylcholine (PC),
sphingophospholipids (SPL), and phosphatidylethanolamine
Table 1 
Patients’ characteristics
No. (M/F) 37 (21/16)
Age (years) 52 ± 10
Duration (years) 6 ± 3
BMI (kg/m2) 23.65 ± 3.52
Hypertension (yes/no) 25/12
Primary causes of end-stage renal disease (%)
Glomerulonephritis 11 (30)
Pyelonephritis 11 (30)
Polycystic kidney disease 7 (19)
Nephropathies endemic 6 (16)
Nephroangiosclerosis 2 (5)
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(PE)] in a one-dimensional TLC system using chloro-
form:methanol:20% ammonia solution (70:25:5, v/v/v) as
the eluting solvent.
After removing the plasma and buff coat, packed eryth-
rocytes (2–3 g) were washed three times with 5 mL of 0.9%
NaCl and separated by centrifugation (3000 r.p.m. for
10 min) before homogenization. The washing solution was
discarded, and the global fraction was frozen at −20°C for
1 h to produce rupture of the erythrocyte membrane. Red
blood cell membrane lipids were extracted by Harth’s
method.[22] The phospholipid fraction was isolated from the
extracted lipids by one-dimensional TLC in a neutral solvent
system hexane-diethyl ether-acetic acid (87:12:1 v/v) using
Silica Gel GF plates (C. Merck, Darmstadt, Germany).
Methyl esters of phospholipid fatty acids (from plasma
and erythrocytes) were preparated by methods reported
previously.[23] Fatty acid methyl esters derivatives formed
from isolated plasma phospholipid fraction were separated
by gas chromatography using a Varian GC (model 3400,
Varian Associates) as described.[24] Individual fatty acid
methyl esters in the sample were identified from the reten-
tion times of authentic standards (Sigma Chemical Co) and/
or polyunsaturated fatty acids (PUFA-2) mixture (Supelco
Inc., Bellefonte). Peak areas were determined with a Varian
4290 integrator, and the results were expressed as the rela-
tive percentage of total identified fatty acids.
Statistical Analyses
All results are expressed as means ± SD. The data
were analyzed by using one-way analysis of variance
model followed by The Fisher exact test,[25] accepting an
alpha level of significance 0.05.
RESULTS
Plasma lipids’ profile of 37 HD patients is shown on
Table 2. Plasma triglyceride (p < 0.001), total cholesterol
(p < 0.05), and total phospholipids (p < 0.01) levels were
significantly higher, and HDL-cholesterol levels signifi-
cantly lower (p < 0.01) in HD patients than in the control
subjects. Plasma PC and PE concentrations were signifi-
cantly higher (p < 0.001) in HD patients. LDL-cholesterol
was not different in plasma of HD patients. Plasma phos-
pholipids distribution (Table 3) showed significantly higher
(p < 0.001) participation of PC and lower (p < 0.001) partic-
ipation of LPC, SPL, and PE (p < 0.01) in HD patients
Plasma and erythrocyte phospholipid fatty acids com-
position in HD patients is shown in Table 4. These results
indicate no difference in plasma phospholipid saturated
fatty acids, significantly higher (p < 0.01) level of oleic
(18:1 n-9), and significantly lower (p < 0.05) levels of
eicopentaenoic (20:5 n-3 EPA) and docosahexaenoic (22:6
n-3 DHA) acids in HD patients. MUFA (monounsaturated
fatty acids) was significantly higher (p < 0.05), and PUFA
n-3 significantly lower (p < 0.05) than in the control sub-
jects. In HD patients, PUFA n-6 was significantly lower
(p < 0.05). However, the fatty acid composition of eryth-
rocyte phospholipid in HD patients was also altered
(Table 4). EPA and DHA levels were significantly lower
(p < 0.05), and consistent with this, PUFA n-3 levels were
significantly lower (p < 0.05) than in control subjects.
DISCUSSION
Dyslipidemia is one of the main risk factors of cardio-
vascular complications in patients with chronic renal
disease.[3,4] There is increasing evidence that hyperlipidemia






patients (n = 37)
Control subjects 
(n = 29)
Triglycerides 2.30 ± 0.29*** 1.38 ± 0.26
Total cholesterol 5.48 ± 0.89* 5.00 ± 0.64
HDL-cholesterol 1.42 ± 0.44** 1.69 ± 0.33
LDL-cholesterol 3.04 ± 0.81 3.13 ± 0.60
Total phospholipids 3.10 ± 0.66*** 2.25 ± 0.35
Phosphatidylcholine 2.16 ± 0.10*** 1.45 ± 0.06
Lysophosphatidylcholine 0.21 ± 0.03 0.21 ± 0.02
Sphingophospholipids 0.57 ± 0.04 0.46 ± 0.02
Phosphatidylethanolamine 0.15 ± 0.02*** 0.12 ± 0.01
The values are means ± SD.
*Significantly different compared to C group, p < 0.05.
**Significantly different compared to C group, p < 0.01.





patients (n = 37)
Control subjects 
(n = 29)
Phosphatidylcholine 69.60 ± 3.14*** 64.40 ± 2.82
Lysophosphatidylcholine 6.96 ± 0.86*** 9.41 ± 0.82
Sphingophospholipids 18.45 ± 1.38*** 20.70 ± 0.99
Phosphatidylethanolamine 4.99 ± 0.82** 5.49 ± 0.38
The values are means ± SD.
*Significantly different compared to C group, p < 0.05.
**Significantly different compared to C group, p < 0.01.
***Significantly different compared to C group, p < 0.001.
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diseases.[1,26] In our study, patients on hemodialysis have
higher levels of plasma triglycerides, total cholesterol, and
lower levels of HDL-cholesterol. Even though low
HDL-cholesterol levels are always associated with
hypertriglyceridemia,[27] it is reasonable to argue that
low HDL-cholesterol is strictly linked to the changes in
triglyceride metabolism.
Abnormal phospholipid metabolism may play an
important role in the progression of atherosclerosis in
patients with end-stage renal disease.[28,29] Plasma phos-
pholipids distribution was altered in HD patients in our
study. In the present data, we have found a significant
decrease in plasma SPL distribution in HD patients. The
in vitro study by Zager[30] showed that SPL could directly
decrease cell/membrane damage. In fact, Zager argued
that SPL could extend potent antiproliferative effects in
the setting of subendotel tubular damage in renal failure.
SPL serves as a critical modulator of membrane fluid-
ity.[31] The importance of phospholipids for the structure
and integrity of cellular membranes suggests that many
functional disturbances in renal failure may be related to
changes in phospholipids distribution and fatty acid com-
position. In our study, disturbance in fatty acid metabolism
in HD is evident. The level of oleic acid (one of MUFA)
in plasma phospholipids was elevated, and the levels of
PUFA, especially EPA and DHA, two n-3 PUFA, was
reduced in plasma and erythrocyte phospholipids. Our
results showing the increase of oleic acid and total MUFA
in patients with chronic renal failure agree with previous
reports.[32,33] De Gomez Dumm et al.[32] found decreased
plasma PUFA in patients on hemodialysis; the lipid com-
position abnormality persisted after 18 months and
became more notorious after 30 months. Varga et al.[33]
concluded that the relative abundance of saturated fatty
acids (SFA) and MUFA in plasma of HD patients is asso-
ciated with concomitant lipid disorders and cardiomyopa-
thy, whereas the low relative abundance of PUFA was
common in all HD patients. Conversely, Reaven et al.[34]
reported that the high oleic acid content in patients with
chronic renal failure might exhibit protective roles.
Studies examining the relationship between blood
individual fatty acid with serum triglycerides and total
cholesterol are not consistent.[35,36] Grimsgarard et al.[37]
reported that the concentration of EPA and DHA and total
n-3 showed inverse association with serum triglycerides,
whereas oleic acid was positively associated with triglyc-
eride concentrations. Plasma triglyceride concentration
represents a functional indicator of n-3 PUFA because n-3
PUFA exerts a consistent hypertriglyceridemic effect,
which is dose dependent and persistent.[38] Decrease in
PUFA, especially n-3 may be a risk factor for depression
often present in patients on hemodialysis.[39] Disturbances
in fatty acid metabolism in HD patients in our study
(increased oleic acid, decreased EPA and DHA) are asso-
ciated with high triglyceride levels. Our results showed
abnormal lipid metabolism (triglycerides and phospholipids)
Table 4 
Plasma and erythrocyte phospholipid fatty acids composition (mol%) in hemodialysis patients
Fatty Acids
Plasma phospholipids Erythrocyte phospholipids
HD patients (n = 37) Controls (n = 29) HD patients (n = 37) Controls (n = 29)
16:0 28.09 ± 3.34 26.46 ± 2.44 21.63 ± 1.85 22.42 ± 2.59
18:0 15.67 ± 3.59 16.14 ± 2.41 19.28 ± 1.49 18.71 ± 1.71
16:1 n-7 0.41 ± 0.26 0.29 ± 0.16 — —
18:1 n-9 13.05 ± 2.21** 11.71 ± 1.24 17.86 ± 1.77 17.53 ± 2.70
18:2 n-6 25.50 ± 2.88 26.47 ± 2.78 14.80 ± 2.01 15.53 ± 1.83
20:3 n-6 1.98 ± 0.50 2.42 ± 0.71 1.26 ± 0.41 1.24 ± 0.44
20:4 n-6 11.06 ± 2.21 11.56 ± 2.32 15.29 ± 1.83 16.25 ± 2.03
22:4 n-6 0.44 ± 0.11 0.39 ± 0.19 3.54 ± 0.86 3.53 ± 1.23
20:5 n-3 0.26 ± 0.14* 0.36 ± 0.14 0.23 ± 0.06* 0.49 ± 0.14
22:5 n-3 0.54 ± 0.14 0.57 ± 0.10 1.21 ± 0.40 1.29 ± 0.46
22:6 n-3 3.00 ± 0.90* 3.63 ± 1.12 4.33 ± 0.83* 5.32 ± 1.10
SFA 43.77 ± 5.23 42.60 ± 3.10 40.91 ± 2.97 41.13 ± 4.84
MUFA 13.45 ± 2.50* 12.00 ± 1.74 17.86 ± 1.77 17.53 ± 2.70
PUFA n-6 38.98 ± 3.28* 40.84 ± 2.86 34.87 ± 3.50 36.59 ± 2.39
PUFA n-3 3.80 ± 1.19* 4.56 ± 1.35 5.96 ± 0.88* 6.93 ± 1.27
n-6/n-3 9.59 ± 1.32 8.82 ± 1.58 5.93 ± 0.91 5.46 ± 1.06
The values are means ± SD.
*Significantly different compared to C group, p < 0.05.
**Significantly different compared to C group, p < 0.01.
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and deficiency of n-3 PUFA that may indicate the risk
and/or progression of atherosclerosis. In addition, pub-
lished data[40] suggested that a high proportion of n-3
PUFA in red blood cell membranes is associated with a
reduced risk of primary cardiac arrest.
In our study, PUFA n-3 (EPA and DHA) decreased in
erythrocyte phospholipids (PUFA n-6 also decreased but
not significantly) and may be connected with lower mem-
brane fluidity in patients with chronic renal failure.[41]
This is because the length and degree of unsaturation of
the membrane phospholipid fatty acid are the main deter-
minants of fluidity.[42] Peuchant et al.[43] found that eryth-
rocytes of patients with chronically renal failure showed
increased lipid peroxidation associated with a reduction in
long-chain PUFA. Abnormal fatty acid metabolism may
contribute to clinical problems such as itching, pruritus,
abnormal perspiration, susceptibility to infection, delayed
wound healing, anemia, and increased hemolysis,[15,38] as
seen in patients on hemodialysis.
Being overweight and hyperlipidemia are established
risk factors in the general population, whereas lower body
mass index and lower plasma cholesterol have been shown
to be risk factors for cardiovascular mortality in end-stage
renal disease.[39,44] Long-term therapy and inadequate diet
regimen in end-stage renal disease (terminal phase) lead to
weight loss. Dialysis procedure may accentuate malnutrition
by removing important nutrients. In addition, malnutrition is
characterized by not only impaired lipid metabolism but also
results in modification of plasma and erythrocyte fatty acid
profile. It is interesting that the studied patients on HD who
have adequate nutrition status also show a deficit of essential
PUFA, particularly n-3 PUFA. Because composition of fatty
acids of serum and erythrocyte phospholipids clearly reflects
dietary habits,[45] we suggest that more attention be given to
the content and composition of dietary fat to prevent distri-
bution in fatty acid metabolism in all patients with end-stage
renal disease and not only in malnutrition ones.
In summary, plasma phospholipids fatty acid profile
in our patients on hemodialysis indicate the necessity of
nutrition care programs and the use of appropriate diet
with adequate n-6/n-3 fatty acid ratio. Well-designed and
controlled studies are needed to determine if supplementa-
tion might lead to prevention or regression of atherosclerosis
and could remove some clinical problems in hemodialyzed
patients.
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